Stock Forecast

  NOXXON Pharma N.V. ( ALNOX.PA) Stock. Should you Buy or Sell?    $ 0.04

0.00 (-2.50 %)



NOXXON Pharma N.V. Analysis

Updated on 08-08-2022
Symbol ALNOX.PA
Price $0.04
Beta 2.238
Volume Avg. $4.35 M
Market Cap $3.05 M
52 Week Range $0.038 - $0.4098


NOXXON Pharma N.V. opened the day at $0.04 which is -2.50 % on yesterday's close. NOXXON Pharma N.V. has a 52 week high of $0.4098 and 52 week low of $0.038, which is a difference of $0.3718. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $3.05 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy NOXXON Pharma N.V. for $3.05 M, it would take 15 years to get your money back. NOXXON Pharma N.V. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




NOXXON Pharma N.V. Stock Forecast - Is NOXXON Pharma N.V. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreSell
DE ScoreSell
PE ScoreStrong Sell
PB ScoreSell
Overall RecommendationNeutral

Growth and Value


PE Ratio -0.001
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing NOXXON Pharma N.V.


Price Book Value Ratio 0.001 Price To Book Ratio 0.001
Price To Sales Ratio 0.000 Price Earnings Ratio -0.001


How liquid is NOXXON Pharma N.V.


Current Ratio 1.841
Quick Ratio 1.801


Debt


Debt Ratio 0.539 Debt Equity Ratio 1.166
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000



Latest news about NOXXON Pharma N.V.






About NOXXON Pharma N.V.


CEO : DR. Aram Mangasarian
Sector : Healthcare
Industry : Biotechnology

Website : https://www.noxxon.com

Exchange : Paris

Description :

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.


My Newsletter

Sign Up For Updates & Newsletters